Trading Signals: SAGE Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Fri. Dec. 22, 2023)(SAGE Therapeutics Inc)
| SAGE latest price $163.2600 (-2.51%) ($161.0100 - $168.3200) on Tue. Feb. 27, 2018. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 9.39% (three month average) | RSI | 38 | Latest Price | $163.2600(-2.51%) | Stocks Behave Similarly | Similar Stock List | Weekly Trend | SAGE declines -1.1% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support SAGE advance at 0% a week (0% probability) IBB(50%) XBI(48%) IWO(46%) IWC(43%) IWM(43%) | Factors Impacting SAGE price | SAGE will decline at least -4.695% in a week (0% probabilities). VIXM(-12%) UUP(-11%) TLT(-7%) SHY(-5%) IGOV(-4%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -4.695% (StdDev 9.39%) | Hourly BBV | 0 () | Intraday Trend | -3% | | | |
|
Resistance Level | $169.2 | 5 Day Moving Average | $162.83(0.26%) | 10 Day Moving Average | $162.79(0.29%) | 20 Day Moving Average | $169.2(-3.51%) | To recent high | -15.1% | To recent low | 81.8% | Market Cap | $8.479b | | | | SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA. |